HDIM
EW icon

Hanson & Doremus Investment Management’s Edwards Lifesciences EW Stock Holding History

Hanson & Doremus Investment Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25K Buy
+312
New +$25.7K ﹤0.01% 390
2024
Q2 		– Sell
-51
Closed -$5K – 461
2024
Q1 		$5K Buy
+51
New +$4.28K ﹤0.01% 439
2023
Q2 		– Sell
-202
Closed -$17K – 453
2023
Q1 		$17K Buy
+202
New +$15.9K ﹤0.01% 387

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Hanson & Doremus Investment Management's EW Position: Q1 2026 in Review

Hanson & Doremus Investment Management opened a new position in Edwards Lifesciences (EW) in Q1 2026: 312 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #390 among its holdings. This is a return to the name: Hanson & Doremus Investment Management previously reported a position in EW as recently as Q1 2024.

Hanson & Doremus Investment Management first reported a position in EW in Q1 2023 and has held it in 3 quarters since. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Hanson & Doremus Investment Management held 312 shares of Edwards Lifesciences worth $25K as of Q1 2026.
  • Edwards Lifesciences was a new Hanson & Doremus Investment Management position in Q1 2026.
  • Edwards Lifesciences made up ﹤0.01% of Hanson & Doremus Investment Management's portfolio in Q1 2026, its #390 holding.
  • Hanson & Doremus Investment Management first reported a position in Edwards Lifesciences in Q1 2023 and has held it in 3 quarters since.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Hanson & Doremus Investment Management's 13F filing for Q1 2026, filed 17 Apr 2026.